SML1639

BRD3308

≥98% (HPLC)

• Synonim(y): 4-Acetamido-N-(2-amino-4-fluorophenyl)benzamide
• Wzór empiryczny (zapis Hilla): C₁₅H₁₄FN₃O₂
• Numer CAS: 1550053-02-5
• Masa cząsteczkowa: 287.29
• UNSPSC Code: 12352200
• PubChem Substance ID: 329825980
• NACRES: NA.77
• eCl@ss: 32160703
• Assay: ≥98% (HPLC)
• Form: powder

Właściwości

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 10 mg/mL, clear
• storage temp.: 2-8°C
• SMILES string: CC(NC1=CC=C(C(NC2=CC=C(F)C=C2N)=O)C=C1)=O
• InChI: 1S/C15H14FN3O2/c1-9(20)18-12-5-2-10(3-6-12)15(21)19-14-7-4-11(16)8-13(14)17/h2-8H,17H2,1H3,(H,18,20)(H,19,21)
• InChI key: RRJDFENBXIEAPD-UHFFFAOYSA-N

Opis

Biochem/physiol Actions

BRD3308 is a highly selective inhibitor of histone deacetylase 3 (HDAC3) with an IC₅₀ value of 65 nM for HDAC3 vs. IC₅₀ values of 1.08 μM and 1.15 μM for HDAC1 and HDAC2, respectively. BRD3308 protected pancreatic β cells, suppressing inflammatory cytokine-induced apoptosis and increasing insulin release without the toxicity associated with HDAC1 and HDAC2 inhibitors. In a rat model of type 2 diabetes, BRD3308 reduced hyperglycemia and increased insulin secretion without affecting weight gain. In another study, BRD3308 was found to activate HIV-1 transcription, disrupting HIV-1 latency.

BRD3308 is a highly selective inhibitor of histone deacetylase 3 (HDAC3).

BRD3308 promotes outgrowth of HIV-1 (human immunodeficiency virus 1) from inactive infected patient cells. It helps to increase β-cell proliferation.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Piktogramy: GHS07
• Słowo ostrzegawcze: Warning
• Kody zagrożeń: H315,H319
• Ostrzeżenia: P264 - P280 - P302 + P352 - P305 + P351 + P338 - P332 + P313 - P337 + P313
• Hazard Classifications: Eye Irrit. 2 - Skin Irrit. 2
• Klasa składowania: 11 - Combustible Solids
• WGK: WGK 3
• Temperatura zapłonu (°F): Not applicable
• Temperatura zapłonu (°C): Not applicable